Original Research Article

Association of metabolic syndrome in patients of vitiligo

Krishnendra Varma¹, Ujjwal Kumar¹, Aishwarya Mahadik¹, Yashdeep Jat¹,*

¹Dept. of Dermatology, RD Gardi Medical College, Ujjain, Madhya Pradesh, India

A R T I C L E   I N F O

Article history:
Received 22-10-2021
Accepted 09-11-2021
Available online 11-12-2021

Keywords:
Vitiligo
Metabolic Syndrome

A B S T R A C T

Background: The metabolic syndrome is the term used to describe a constellation of metabolic derangements that includes insulin resistance, hypertension, Dyslipidemia, central or visceral obesity, type 2 DM & accelerated cardiovascular disease. An oxidative imbalance is responsible for the development of both metabolic syndrome & vitiligo.

Aim: In the present study we have evaluated the association of metabolic syndrome with Vitiligo.

Materials and Methods: In this observational cross-sectional study we selected 40 subjects attending skin OPD with age matched 40 controls and assessed the waist circumference, blood pressure, serum triglyceride level, cholesterol and high-density cholesterol along with Fasting blood glucose level at tertiary care Hospital. A detailed history including age, gender, diabetes mellitus, hypertension, smoking and onset of vitiligo was taken. The MetS criteria were defined by National Cholesterol Education Program Adult Treatment Panel III 2005 (ATP III) guidelines.

Results: We identified metabolic syndrome in 15 subjects with vitiligo and 6 subjects without vitiligo.

The P value came 0.022 which is statistically significant. Active vitiligo, segmental vitiligo and increased duration of vitiligo were determined to be independent predictors of metabolic syndrome.

Conclusion: The risk of developing metabolic syndrome is increased in patients of vitiligo. Screening and the close follow up of the patients of vitiligo with clinical feature such as in unstable, segmental vitiligo with increased duration is necessary for the early diagnosis of the metabolic syndrome to reduce the morbidity & mortality of the patients.

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

Vitiligo is an acquired disorder of the skin and mucous membranes that is characterized by well circumscribed macules and patches and that occurs secondarily to selective destruction of melanocytes.¹

The vitiligo has complex, multifactorial and largely unknown etiopathogenesis. Several theories have been proposed to explain the pathogenesis of vitiligo such as role of genetics, oxidative stress, autoimmune, neurohumoral, melanocytorrhagy, viral infection and autotoxicity.²

Although none of them is mutually exclusive, and it is likely that they each contribute partially towards it.¹

The prevalence of vitiligo ranges from 0.5% to 1%. Its highest incidence has been reported amongst Indians from the Indian subcontinent. India is considered to have the highest prevalence in the world, at about 8.8%. Mexico and Japan also has high prevalence of vitiligo.²

The metabolic syndrome or the insulin resistance syndrome are the terms used to describe a constellation of metabolic derangements that includes insulin resistance, hypertension, Dyslipidemia, central or visceral obesity, type 2 DM & accelerated cardiovascular disease.³
An oxidative imbalance is responsible for the development of both metabolic syndrome & vitiligo. Melanin in the adipose tissue has both anti-inflammatory and antioxidant effects. A lower number of melanocytes as well as decreased melanogenesis in the adipose tissue might reduce the anti-inflammatory effects of the Melanocytes and cause an increased production of the free oxygen radicals in vitiligo which is responsible for the metabolic syndrome. Other mechanism may contribute to the development of metabolic syndrome in patients of vitiligo such as insulin resistance, lipid profile disturbances & other metabolic disorders, due to the increased inflammatory cytokines and autoimmune reactions of the melanocytes.

2. Materials and Methods

Total forty (40) patients with clinically diagnosed vitiligo and forty (40) age & sex matched controls were chosen and written consent was taken to participate during the study period. A detailed history of onset, duration, progression and associated symptoms were obtained from the patients and their parents. Relevant past history, family history and drug intake prior the onset of the disease is recorded. General and systemic examination was done.

Dermatological examination was carried out. Morphology, distribution, progression and various special features were recorded. Oral and genital mucosa were examined. All routine investigations including haemoglobin, total leukocyte count, differential count, hepatic and renal profile was done. Special investigation like Lipid Profile, Fasting blood sugar level & Body mass index (BMI) measurement was done. The results was analysed and discussed in detail.

2.1. Inclusion criteria

1. All new patients with vitiligo presenting to RDGMC institution.
2. All male/female patients of age group 10-80 yrs.
3. Patients who have given consent for the study.

2.2. Exclusion criteria

1. Patients who are not cooperative or not willing to participate in the study.
2. Immunocompromised patients.

3. Results

As per national cholesterol education program (2001, 2005). Metabolic syndrome diagnosis is made when there is presence of three or more of the following five:

In our study total 40 vitiligo patients were assessed with 40 age matched control subjects. Fasting Glucose, Cholesterol Triacylglycerol, LDL, HDL, Waist Circumference, Systolic and diastolic blood pressure were measured. There was significant difference was observed in Fasting Glucose level in cases when compared to control with p value of 0.03. Waist Circumference and blood pressure (systolic & diastolic) also showed significant difference when compared to control. In Vitiligo patients the level of serum Triglyceride was found higher and shows highly significant when compared with control with a P value of 0.033. The levels of HDL in Vitiligo patients were highly significant when compared with control With a P value of. In our study Metabolic syndrome was present in 15 cases in comparision to 6 controls which came out to be statistically significant with a p-value of 0.022.

4. Discussion

The etiopathogenesis of Vitiligo is complex, multifactorial and largely unknown. The initial event in pathophysiology is considered to be the intrinsic defect in melanocytes. In this, oxidative stress in melanocytes is leading to a local inflammatory response and the start of innate immune processes, which in subjects genetically predisposed individual leads to development of autoimmunity, forms melanocyte-specific cytotoxic immune responses. Similarly in Metabolic syndrome. Oxidative stress plays an important role leading to its development. In this syndrome accumulation of plasma free fatty acid increases the production of Reactive Oxygen Species by stimulating NOX and decreasing the antioxidant enzyme activity resulting in disturbance in glucose metabolism,
Table 3: On comparison above studies with our study following results was obtained

| Parameters       | Our study Cases (Mean±SD) | Controls (Mean±SD) | H. Atas, M. Gönül Cases (Mean±SD) | Controls (Mean±SD) |
|------------------|---------------------------|--------------------|-----------------------------------|--------------------|
| Fasting blood glucose | 104±14.3                  | 116.6±10.8         | 97.1±26.1                         | 113±11             |
| Systolic blood pressure | 116.6±10.8               | 76.4±5.2           | 114±12                            | 119±12             |
| Diastolic blood pressure | 86.2±12.4                 | 75.2±10.8          | 174±21.55                        | 119±12             |
| Waist Circumference | 119±12                    | 81±14              | 119±12                            | 119±12             |
| S. Triglyceride  | 104±14.3                  | 116.6±10.8         | 97.1±26.1                         | 113±11             |
| S. LDL           | 104±14.3                  | 116.6±10.8         | 97.1±26.1                         | 113±11             |

Thus oxidative stress is major reason due to which there is increased predisposition of developing metabolic syndrome in patients of vitiligo.

In our present study Metabolic syndrome was present in 15 vitiligo cases in comparison to 6 non vitiligo cases.

This variable too had statistically significant association with vitiligo like other previously done studies.

P. K. Sinha, Prashant Nigam, J. P. Swain In the study, they selected 75 subjects with age matched 75 controls and they found significant differences in Serum HDL (p < 0.001), and Triglyceride levels (p < 0.001) only. However, In this study there was no significant difference in waist circumference, plasma glucose and blood pressure between cases and controls. Thus the study observed interrelation between Vitiligo and development of metabolic syndrome.

In another study conducted by Hatice Ataş, Müzeyyen Gönül Metabolic Syndrome was diagnosed in 24 (38.1%) subjects with vitiligo and 14 (21.5%) subjects without vitiligo. No significant differences were observed in the age, gender or other demographic or clinical characteristics, except for Metabolic Syndrome in between the vitiligo and control groups. (116) Active vitiligo, segmental vitiligo, increased duration of vitiligo and were determined as independent predictors for Metabolic Syndrome. (117)

5. Conclusion
This study was directed to assess the association of Metabolic Syndrome in patients with vitiligo. Our study showed that All the variables in lipid Profile i.e. Triglyceride, HDL, VLDL were Significantly deranged in the vitiligo group in comparison to non vitiligo group and also p-value of each parameters came out to be statistically significant. Screening and the close follow-up of vitiligo patients with poor clinical features, as in active, extended, segmental vitiligo with an increased duration, for the early diagnosis and treatment of MetS, can reduce the morbidity and mortality.

6. Conflict of Interest
No conflict of interest was declared by the authors.

7. Source of Funding
None.
References

1. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. A comprehensive overview. Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473–91. doi:10.1016/j.jaad.2010.11.030

2. Sehgal VN, Srivastava G. Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol. 2007;73(3):149–56. doi:10.4103/0378-6323.32708

3. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–52. doi:10.1161/CIRCULATIONAHA.105.169404

4. Maresca V, Roccella M, Roccella F. Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo. J Invest Dermatol. 1997;109(3):310–3.

5. Birol A, Kisa U, Kurtipek GS, Kara F, Kocak M, Erkek E, et al. Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo. Int J Dermatol. 2006;45(8):992–3. doi:10.1111/j.1365-4632.2006.02754.x

6. Moretti S, Spallanzani A, Amato L, Hautmann G, Gallerani I, Fabbri P, et al. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res. 2002;15(2):87–92. doi:10.1111/j.1365-4632.2002.00904.x

7. Zeller M, Steg PG, Ravisry J, Laurent Y, Janin-Manificat L, Huillier I, et al. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Inten Med. 2005;165(10):1192–8. doi:10.1001/archinte.165.10.1192

8. Atas H, Göniç M. The Increased Risk of Metabolic Syndrome in Patients with Vitiligo. Balkan Med J. 2017;34(3):219–25.

9. Sinha PK, Nigam P, Swain JP. Metabolic syndrome in vitiligo. Dermatol Ther. 2012;25(1):41–4.

10. Ezzedine K, Lim HW, Suzuki T. Revised classification/nomenclature of vitiligo and related issues: The Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25(3):1–13.

11. Jimbow K, Chen H, Park JS. Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo. Br J Dermatol. 2001;144(1):55–65.

12. Eskandani M, Golchai J, Pirooznia N. Oxidative stress level and tyrosinase activity in vitiligo patients. Indian J Dermatol. 2010;55(1):15–9.

Author biography

Krishnendra Varma, Professor and Head

Ujjwal Kumar, Professor

Aishwarya Mahadik, Assistant Professor

Yashdeep Jat, 3rd Year Resident

Cite this article: Varma K, Kumar U, Mahadik A, Jat Y. Association of metabolic syndrome in patients of vitiligo. IP Indian J Clin Exp Dermatol 2021;7(4):337-340.